問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Shin Kong Memorial Wu Ho-Su Hospital (在職)

Division of Neurology

Linkou Chang Gung Medical Foundation (在職)

Division of Neurology

更新時間：2023-09-19

徐榮隆Hsu, Jung-Lung
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • tulu@cgmh.org.tw

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐榮隆

List

28Cases

2017-08-01 - 2020-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Suspended1Sites

林昆儒
Linkou Chang Gung Medical Foundation

Division of Nuclear Medicine

2017-08-01 - 2020-07-31

Phase I/II

A Noval Tau Tracer ([18F]PM-PBB3) in Young Onset Dementia: Clinical and Neuroimaging Study

  • Condition/Disease

    Alzheimer's Disease,Vascular Dementia,Dementia

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] THK-5351

Participate Sites
2Sites

Terminated2Sites

2015-12-01 - 2021-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer′s Disease

  • Condition/Disease

    Alzheimer′s disease

  • Test Drug

    Aducanumab

Participate Sites
8Sites

Terminated7Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2007-12-04 - 2010-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-01-01 - 2012-07-31

Phase III

Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    LY450139

Participate Sites
5Sites

Terminated5Sites

2010-01-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-08-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-08-01 - 2012-07-31

Phase III

Effect of Passive Immunization on the Progression of Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated10Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB